# ZZedc FDA Compliance Requirements Analysis

**Date**: December 2025
**Status**: Analysis of FDA requirements for clinical trial EDC systems
**Scope**: FDA regulations for electronic data capture, records, and submissions

---

## EXECUTIVE SUMMARY

FDA regulations for electronic data capture in clinical trials focus on **data integrity, security, and auditability** while GDPR focuses on **individual data subject rights, consent, and data minimization**.

**Key Finding**: ZZedc needs **7-9 additional features** beyond GDPR compliance to meet FDA requirements for regulated pharmaceutical trials.

| Requirement | FDA Focus | GDPR Focus | Current ZZedc Status |
|-------------|-----------|-----------|----------------------|
| **Audit Trail** | ‚úÖ Comprehensive | ‚úÖ Comprehensive | ‚úÖ Implemented |
| **Data Integrity** | ‚úÖ ALCOA+ | ‚ö†Ô∏è Basic | ‚ö†Ô∏è Partial |
| **Electronic Signatures** | ‚úÖ Critical | ‚ö†Ô∏è Not primary | ‚ö†Ô∏è Designed, not implemented |
| **System Validation** | ‚úÖ Critical | ‚ùå Not required | ‚ùå Not implemented |
| **User Access Control** | ‚úÖ Role-based | ‚úÖ Role-based | ‚úÖ Implemented |
| **Data Subject Rights** | ‚ö†Ô∏è Limited | ‚úÖ Comprehensive | ‚ö†Ô∏è Designed, not implemented |
| **Encryption** | ‚úÖ At rest & transit | ‚úÖ Critical | ‚ùå Not implemented |
| **Data Retention** | ‚úÖ Per protocol | ‚úÖ Per GDPR | ‚ö†Ô∏è Designed, not implemented |
| **Protocol Compliance** | ‚úÖ Critical | ‚ùå Not relevant | ‚ùå Not implemented |
| **Device/Risk Management** | ‚úÖ Critical | ‚ùå Not relevant | ‚ùå Not implemented |

---

## PART 1: FDA REGULATIONS FOR ELECTRONIC RECORDS IN CLINICAL TRIALS

### 1.1 21 CFR Part 11: Electronic Records; Electronic Signatures

**Purpose**: Establishes criteria for the acceptability of electronic records and signatures in FDA-regulated industries

**Key Requirements**:

#### A. System Controls & Validation

1. **System Validation** (Part 11.10(a))
   - Installation Qualification (IQ): System meets design specifications
   - Operational Qualification (OQ): System performs as designed under normal use
   - Performance Qualification (PQ): System consistently performs under expected conditions
   - Combined into IQ/OQ/PQ documentation

2. **System Documentation** (Part 11.10(b))
   - Standard Operating Procedures (SOPs)
   - Change control procedures
   - System architecture documentation
   - Data flow diagrams
   - Security procedures

3. **User Access Controls** (Part 11.100)
   - ‚úÖ Unique user identification
   - ‚úÖ Password requirements (complexity, aging)
   - ‚úÖ System access authorization lists
   - ‚úÖ Manual or automated logout
   - Session timeout controls
   - Role-based access

#### B. Audit Trail Requirements (Part 11.100(b))

**Current ZZedc Status**: ‚úÖ IMPLEMENTED

- ‚úÖ Independent audit trail (separate from main database)
- ‚úÖ Chronological record of system use
- ‚úÖ Identify user performing action
- ‚úÖ Date and time of action
- ‚úÖ Type of action (CREATE, UPDATE, DELETE, EXPORT)
- ‚úÖ Record reference
- ‚úÖ Original and modified values
- ‚úÖ Secure, computer-generated, time-stamped
- ‚úÖ Protected from modification/deletion
- ‚úÖ Hash-chain integrity verification

**Gaps**:
- ‚ùå Audit trail NOT immutable (could be modified with database access)
- ‚ö†Ô∏è Hash chain validation not automated
- ‚ö†Ô∏è No backup/restore procedures documented

#### C. Data Integrity - ALCOA+ Principles

FDA expects data to meet **ALCOA+** criteria:
- **A**ttributable: Who entered it, when, why
- **L**egible: Readable, clear
- **C**ontemporaneous: Entered at time of observation
- **O**riginal: Source, not a copy
- **A**ccurate: Correct and complete
- **Plus**: Complete, Consistent, Enduring, Available

**Current ZZedc Status**: ‚ö†Ô∏è PARTIAL

| ALCOA+ | Requirement | ZZedc Status | Gap |
|--------|-------------|-------------|-----|
| **A** | Audit trail with user/timestamp | ‚úÖ Yes | None |
| **L** | Data validation, no corruption | ‚ö†Ô∏è Partial | Need format validation |
| **C** | Timestamp at entry, not backdating | ‚ö†Ô∏è Partial | No backdating prevention |
| **O** | Keep original, mark if modified | ‚úÖ Yes | Implemented |
| **A** | Validation rules, range checks | ‚ö†Ô∏è Planned | DSL validation pending |
| **+Complete** | All required fields present | ‚ö†Ô∏è Partial | Need mandatory field enforcement |
| **+Consistent** | Data meets standards | ‚ö†Ô∏è Partial | Need standardization rules |
| **+Enduring** | Permanently retained | ‚ö†Ô∏è Partial | Depends on protocol/legal hold |
| **+Available** | Retrievable, searchable | ‚ö†Ô∏è Partial | Need advanced search/export |

#### D. Electronic Signatures (Part 11.100(a))

**FDA Requirements**:
- Handwritten or electronic signature
- Unique identification of signer
- Date and time of signature
- Intent to sign (acknowledgment)
- Security controls to prevent forgery

**Current ZZedc Status**: üü° DESIGNED, NOT IMPLEMENTED

**Required Features**:
- [ ] e-signature capture (document signing)
- [ ] Timestamp signing
- [ ] Certificate-based signatures (optional but best practice)
- [ ] Audit trail of signature attempts
- [ ] Signature validation
- [ ] Inability to sign on behalf of others without audit trail

### 1.2 FDA Data Integrity Guidance (FDA-2018-D-5945)

**Five Pillars of Data Integrity**:

1. **Data Governance**
   - Clear roles and responsibilities
   - Data stewardship
   - Master data management
   - Data quality standards

2. **System Validation**
   - Prospective validation
   - Retrospective validation
   - Change control

3. **Transparency & Traceability**
   - Complete audit trail
   - Timestamped records
   - User attribution

4. **Control & Assurance**
   - Access controls
   - Change control
   - Error detection/correction

5. **Integrity Risk Assessment**
   - Risk identification
   - Risk mitigation
   - Continuous monitoring

**Current ZZedc Status**: ‚ö†Ô∏è 40-50% IMPLEMENTED

| Pillar | Current State | Gap |
|--------|---------------|-----|
| Governance | ‚ö†Ô∏è Designed | Need role definitions, SOP templates |
| Validation | ‚ùå None | Need IQ/OQ/PQ framework |
| Traceability | ‚úÖ Good | Minor audit trail gaps |
| Control | ‚ö†Ô∏è Partial | Need change control, validation DSL |
| Risk Assessment | ‚ùå None | Need FMEA, DPIA tools |

### 1.3 FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations

**Key Requirements**:

1. **Study Protocol Compliance**
   - Prevent entry of data outside protocol parameters
   - Flag protocol deviations
   - Link data to protocol sections
   - Audit trail of deviation handling

2. **Data Correction & Amendment**
   - Never delete original entry
   - Clearly mark corrections
   - Explain reason for correction
   - Original entry visible
   - Approver signature

3. **Missing Data Handling**
   - Document intended vs. actual data collection
   - Audit trail of missing data decisions
   - Justification for missing observations

4. **Reconciliation Procedures**
   - Reconcile EDC with source documents
   - Document any discrepancies
   - Approval trail

5. **Backup & Recovery**
   - Regular, documented backups
   - Recovery procedures tested
   - Data integrity verified post-recovery

6. **System Access**
   - Unique user IDs
   - Password controls
   - Automatic timeout
   - Secure login tracking

---

## PART 2: FDA vs GDPR COMPARISON

### Similarities (Overlapping Requirements)

| Requirement | FDA | GDPR | Implementation |
|-------------|-----|------|-----------------|
| **Audit Trail** | Part 11.100(b) | Articles 25, 28, 32 | ‚úÖ ZZedc has both |
| **User Access Control** | Part 11.100(a) | Articles 25, 28 | ‚úÖ ZZedc implemented |
| **Encryption** | Part 11 guidance | Article 32 | ‚ùå Not implemented |
| **Data Integrity** | ALCOA+ | Article 5, 32 | ‚ö†Ô∏è Partial |
| **Data Retention** | Protocol-based | Article 5(1)(e) | ‚ö†Ô∏è Designed |
| **System Security** | Part 11.100 | Article 32 | ‚ö†Ô∏è Partial |
| **Change Control** | Part 11.10(b) | Article 25 | ‚ö†Ô∏è Designed |
| **Document Retention** | Regulatory hold | Legal hold | ‚ö†Ô∏è Designed |

### Key Differences (FDA-Specific)

| Aspect | FDA Focus | GDPR Focus | ZZedc Gap |
|--------|-----------|-----------|----------|
| **Regulatory Focus** | Data integrity & auditability | Individual rights & consent | Moderate |
| **Enforcement** | "Predicate rule" studies | All processing of EU residents | High (FDA stricter) |
| **Data Deletion** | ‚ùå Not allowed (retention mandated) | ‚úÖ Right to erasure (Article 17) | CONFLICT - need legal hold |
| **Retroactive Access** | ‚úÖ Allowed (audit trail covers) | ‚ùå Can't monitor all access | High (FDA allows more) |
| **Consent Model** | Broad (one-time for trial) | Granular (each purpose) | High (different approaches) |
| **Subject Rights** | Minimal | Comprehensive (7 rights) | High (GDPR more demanding) |
| **System Validation** | ‚úÖ Mandatory | ‚ùå Not required | Critical gap for FDA |
| **e-Signatures** | ‚úÖ Critical | ‚ö†Ô∏è Optional | Critical gap for FDA |
| **Protocol Adherence** | ‚úÖ Central to compliance | ‚ùå Not relevant | Critical gap for FDA |

### Conflict Resolution: Regulated Pharmaceutical Trials (FDA + GDPR)

**Problem**: GDPR Article 17 (Right to Erasure) conflicts with FDA requirement to retain all trial data

**ZZedc Solution Architecture** (Already designed):
- GDPR deletion request triggers "anonymization hold"
- Data marked as restricted (GDPR Article 18)
- Original identifiers deleted/encrypted
- Data retained for regulatory hold
- Audit trail of deletion request + hold reason
- Both regulations satisfied

**Implementation Status**: üü° DESIGNED, NOT IMPLEMENTED

---

## PART 3: ADDITIONAL FDA-SPECIFIC FEATURES NEEDED

### Feature 1: System Validation (IQ/OQ/PQ) Framework

**FDA Requirement**: 21 CFR Part 11.10(a)
**Current Status**: ‚ùå NOT IMPLEMENTED
**Feasibility**: üü° MODERATE (2-3 weeks)
**Priority**: üî¥ CRITICAL for regulated trials

**Implementation**:
- [ ] IQ Document Generator
  - System specifications checklist
  - Hardware/software inventory
  - Network architecture diagram
  - Database specifications
  - Auto-generate from package metadata

- [ ] OQ Execution Framework
  - Test case templates (50+)
  - Automated regression testing
  - Test execution logging
  - Pass/fail documentation
  - Evidence collection (screenshots, logs)

- [ ] PQ (Performance Qualification)
  - Performance benchmarks
  - Load testing (1000+ concurrent users)
  - Data volume testing
  - Backup/recovery testing
  - Disaster recovery testing

- [ ] Summary Report
  - Auto-generate PDF IQ/OQ/PQ document
  - Dated, signed certification
  - Risk assessment matrix
  - Change control procedures

**Effort**: 2-3 weeks
**Skills**: Testing frameworks, R code introspection, PDF generation

---

### Feature 2: Protocol Compliance Monitoring

**FDA Requirement**: Guided by "Computerized Systems Used in Clinical Investigations"
**Current Status**: ‚ùå NOT IMPLEMENTED
**Feasibility**: üü° MODERATE (3-4 weeks)
**Priority**: üî¥ CRITICAL for regulated trials

**Implementation**:
- [ ] Protocol Upload & Parsing
  - Upload study protocol PDF
  - Link data dictionary to protocol sections
  - Tag data items to protocol objectives
  - Map visits/assessments to protocol schedule

- [ ] Protocol Deviation Tracking
  - Flag unscheduled visits
  - Monitor visit windows
  - Track assessment completeness per protocol
  - Document deviation reason
  - Manager approval workflow

- [ ] Eligibility Criteria Enforcement
  - Define inclusion/exclusion rules
  - Prevent enrollment of ineligible subjects
  - Audit trail of eligibility checks
  - Waiver/exception tracking

- [ ] Assessment Schedule Monitoring
  - Expected visits calendar
  - Actual vs. expected comparisons
  - Early/late visit flags
  - Missing assessment alerts

- [ ] Protocol Amendment Handling
  - Version control of protocol
  - Amendment effective dates
  - Retroactive data handling
  - Audit trail of changes

**Effort**: 3-4 weeks
**Skills**: NLP for protocol parsing, calendar logic, rule engine

---

### Feature 3: Enhanced Data Correction Workflow

**FDA Requirement**: 21 CFR Part 11, Part 312.62 (IND Safety Reports)
**Current Status**: ‚ö†Ô∏è PARTIAL (correction tracking exists, workflow incomplete)
**Feasibility**: üü¢ EASY (2-3 weeks)
**Priority**: üî¥ CRITICAL

**Implementation**:
- [ ] Data Correction Request Form
  - Original value (read-only)
  - Corrected value
  - Reason for correction (dropdown: typo, source doc error, calculation error, etc.)
  - Original source document reference
  - Corrected source document reference

- [ ] Approval Workflow
  - Submitter (CRA, investigator, coordinator)
  - Approver (PI, data manager)
  - Timestamps for each step
  - Electronic signature/initials

- [ ] Audit Trail
  - Original entry: user, date/time, value
  - Correction request: user, date/time, reason
  - Approval: user, date/time, signature
  - Visibility of all states

- [ ] Restricted Data Handling
  - Cannot correct locked/finalized data without DM override
  - Override tracked with justification
  - Escalation for queries vs. corrections

- [ ] Report Generation
  - Data correction report (for regulatory submission)
  - Correction rate by site/form
  - Most common correction types

**Effort**: 2-3 weeks
**Skills**: Shiny forms, workflow, approval logic

---

### Feature 4: Study Reconciliation & Closeout

**FDA Requirement**: Part 312.62, GCP E6
**Current Status**: ‚ùå NOT IMPLEMENTED
**Feasibility**: üü° MODERATE (3-4 weeks)
**Priority**: üü° HIGH (needed before study closeout)

**Implementation**:
- [ ] Subject Reconciliation Checklist
  - All required visits completed?
  - All required assessments entered?
  - All values within expected ranges?
  - No critical data missing?
  - All corrections approved?
  - All queries resolved?

- [ ] Query Management
  - Auto-generate queries for missing data
  - Out-of-range values
  - Inconsistent values
  - Protocol deviations
  - Track query response time (3-day SLA typical)

- [ ] Data Lock Procedures
  - Data lock checklist
  - Final data review
  - Lock date/time
  - Lock certification
  - Locked data read-only
  - Post-lock corrections tracked separately

- [ ] Study Closeout Report
  - Subject disposition (enrolled, completed, withdrew, etc.)
  - Data completeness summary
  - Query resolution summary
  - Data corrections summary
  - Protocol deviations summary
  - Regulatory hold confirmation

**Effort**: 3-4 weeks
**Skills**: Workflow logic, reporting, checklist systems

---

### Feature 5: Adverse Event (AE) Management & Safety Reporting

**FDA Requirement**: 21 CFR 312.32 (Investigator's Brochure), 312.62 (Safety Reports)
**Current Status**: ‚ùå NOT IMPLEMENTED
**Feasibility**: üü° MODERATE (3-4 weeks)
**Priority**: üî¥ CRITICAL for safety

**Implementation**:
- [ ] AE/SAE Capture Form
  - Event description (system, term, severity)
  - Onset date/time
  - Duration
  - Outcome (ongoing, resolved, resolved with sequelae, fatal)
  - Relationship to study drug (unrelated, unlikely, possible, probable, definite)
  - Action taken
  - Outcome

- [ ] SAE Detection & Escalation
  - Auto-flag serious AEs (hospitalization, death, disability, etc.)
  - 24-hour SAE reporting rule enforcement
  - Email alerts to PI/safety officer
  - Audit trail of notification

- [ ] Safety Reporting
  - Expedited reporting (IND Safety Report) ‚Äì 7 days
  - Periodic safety update report (PSUR) ‚Äì annually
  - Alert report for unexpected serious events

- [ ] Safety Monitoring
  - Real-time AE dashboard
  - AE incidence tracking
  - Severity trends
  - Relationship analysis
  - Signal detection (unusual patterns)

- [ ] Regulatory Submission
  - Export AE data in FDA format
  - FAERS submission support
  - IND safety report generation

**Effort**: 3-4 weeks
**Skills**: Medical terminology, event classification, risk assessment

---

### Feature 6: Electronic Signatures (e-Signature) Implementation

**FDA Requirement**: 21 CFR Part 11.100(a)
**Current Status**: üü° DESIGNED, NOT IMPLEMENTED
**Feasibility**: üü° MODERATE (2-3 weeks)
**Priority**: üî¥ CRITICAL for regulatory submission

**Implementation**:
- [ ] e-Signature Capture
  - Typed signature (name + initials)
  - Password/PIN verification
  - Timestamp capture
  - Intent statement ("I certify this data is correct")
  - Audit trail of signature attempt

- [ ] Signature Types
  - Data entry sign-off (initial entry)
  - Correction approval
  - Query resolution
  - Data lock certification
  - Form finalization
  - Protocol deviation approval

- [ ] Signature Validation
  - Cannot sign data someone else entered (audit trail verification)
  - Signature intent clear
  - Cannot unsign (only new signature to supersede)
  - Signed document locked from editing

- [ ] Certificate Support (Optional)
  - Digital certificate option (X.509)
  - PKI infrastructure integration
  - Enhanced security for critical signatures

- [ ] Audit Trail
  - Signature timestamp
  - Signer identity
  - Data signed (hash)
  - Signature attempt history
  - Failed signature attempts

**Effort**: 2-3 weeks
**Skills**: Cryptography, Shiny widgets, audit logging

---

### Feature 7: Change Control & Configuration Management

**FDA Requirement**: 21 CFR Part 11.10(b)
**Current Status**: ‚ö†Ô∏è DESIGNED, NOT FULLY IMPLEMENTED
**Feasibility**: üü° MODERATE (2-3 weeks)
**Priority**: üü° HIGH

**Implementation**:
- [ ] Change Request System
  - What changed (form structure, validation rule, user role, database schema)
  - Who proposed it (user ID, date)
  - Reason for change (bug fix, enhancement, regulatory update)
  - Risk assessment
  - Testing required

- [ ] Change Approval Workflow
  - Requestor ‚Üí Reviewer ‚Üí Approver (change control board)
  - Impact analysis
  - Testing verification
  - Release notes generation

- [ ] Version Control
  - Form versions (v1.0, v1.1, etc.)
  - Validation rule versions
  - User role changes (effective date)
  - Database schema changes (migrations)

- [ ] Rollback Capability
  - Ability to revert changes if needed
  - Data reconciliation after rollback
  - Audit trail of rollback decision

- [ ] Documentation
  - All changes documented
  - Rationale recorded
  - Testing evidence attached
  - Approval signatures
  - Release to production record

**Effort**: 2-3 weeks
**Skills**: Database migrations, version control, Shiny workflows

---

### Feature 8: Data Backup, Archive & Recovery

**FDA Requirement**: 21 CFR Part 11.10(b)
**Current Status**: ‚ö†Ô∏è PARTIAL (backup code exists, procedures not documented)
**Feasibility**: üü¢ EASY (1-2 weeks)
**Priority**: üü° HIGH

**Implementation**:
- [ ] Backup Strategy
  - Daily incremental backups
  - Weekly full backups
  - Monthly archive (long-term retention)
  - Off-site backup replication
  - Backup encryption

- [ ] Backup Verification
  - Automated integrity checks (file hashes)
  - Periodic restore testing
  - Backup metadata (date, size, hash)
  - Backup audit trail

- [ ] Archive & Retrieval
  - Long-term storage (7+ years for FDA trials)
  - Media preservation (prevent data decay)
  - Retrieval procedures
  - Retrieval audit trail

- [ ] Disaster Recovery
  - Recovery Time Objective (RTO)
  - Recovery Point Objective (RPO)
  - Tested recovery procedures
  - Recovery documentation
  - Recovery drills (annual)

- [ ] Documentation
  - Backup/recovery SOP
  - Backup schedule
  - Recovery procedures
  - Contact information for emergencies

**Effort**: 1-2 weeks
**Skills**: Database administration, backup tools, documentation

---

### Feature 9: Regulatory Submission Data Package

**FDA Requirement**: IND/NDA/BLA submission requirements
**Current Status**: ‚ùå NOT IMPLEMENTED
**Feasibility**: üü° MODERATE (3-4 weeks)
**Priority**: üî¥ CRITICAL (only needed before submission)

**Implementation**:
- [ ] Safety Database Export
  - Individual Case Safety Reports (ICSRs)
  - Expedited reports
  - Periodic safety updates
  - FAERS format

- [ ] Efficacy Database Export
  - Demographic data
  - Efficacy assessments
  - Analysis datasets (ADaM format)
  - Study summary (CDISC SDTMv1.6)

- [ ] Study Documentation Package
  - Protocol (with amendments)
  - IB (Investigator's Brochure)
  - Quality overall summary
  - Environmental assessment
  - Previous human experience

- [ ] Electronic Data Submission
  - eCopy (FDA electronic submission)
  - Validated data format
  - Metadata included
  - File integrity verification

- [ ] Regulatory Tracking
  - Submission dates
  - FDA meeting dates
  - Complete Response Letter (CRL) items
  - Amendment tracking

**Effort**: 3-4 weeks
**Skills**: Regulatory knowledge, data formatting, CDISC standards

---

## PART 4: IMPLEMENTATION ROADMAP FOR FDA COMPLIANCE

### Priority Tier 1: CRITICAL (Block pharmaceutical trials without these)

**Timeline**: 4-5 weeks
**Effort**: 2 developers

1. **System Validation Framework** (IQ/OQ/PQ) ‚Äì 2 weeks
   - Auto-generate IQ checklist from codebase
   - OQ testing framework (regression tests)
   - PQ performance testing
   - PDF report generation

2. **Protocol Compliance Monitoring** ‚Äì 3 weeks
   - Protocol upload & parsing
   - Visit schedule enforcement
   - Assessment completeness tracking
   - Deviation documentation

3. **Enhanced Data Correction Workflow** ‚Äì 2 weeks
   - Correction request form
   - Approval workflow
   - Detailed audit trail
   - Report generation

**Impact**: Enables FDA-regulated pharmaceutical trials

---

### Priority Tier 2: HIGH (Needed for quality pharmaceutical operations)

**Timeline**: 4-5 weeks
**Effort**: 1-2 developers

1. **Study Reconciliation & Closeout** ‚Äì 3-4 weeks
   - Subject reconciliation checklist
   - Query management system
   - Data lock procedures
   - Closeout reporting

2. **Adverse Event Management** ‚Äì 3-4 weeks
   - AE/SAE capture forms
   - Safety alert escalation
   - FAERS submission export
   - Safety monitoring dashboard

3. **Electronic Signatures** ‚Äì 2-3 weeks
   - Signature capture
   - Validation logic
   - Audit trail
   - Certificate support (optional)

**Impact**: Meets modern FDA expectations for electronic trials

---

### Priority Tier 3: MEDIUM (Enhances compliance confidence)

**Timeline**: 3-4 weeks
**Effort**: 1 developer

1. **Change Control System** ‚Äì 2-3 weeks
   - Change request workflow
   - Impact analysis
   - Version control
   - Release documentation

2. **Backup/Recovery Procedures** ‚Äì 1-2 weeks
   - Automated backup verification
   - Recovery testing framework
   - Disaster recovery documentation

3. **Regulatory Submission Package** ‚Äì 3-4 weeks
   - Export templates for IND/NDA/BLA
   - Data formatting (CDISC)
   - Metadata inclusion
   - Validation rules

**Impact**: Meets regulatory submission requirements

---

## PART 5: GDPR + FDA COMPLIANCE STRATEGY FOR ZZEDC

### For Academic Research (GDPR + Limited FDA)
**Features Needed**:
- ‚úÖ GDPR compliance (data subject rights, consent, encryption)
- ‚úÖ Audit trail (for GDPR + basic FDA)
- ‚ö†Ô∏è Limited FDA: data corrections, query management

**Timeline**: 5-6 weeks
**Developers**: 1-2

---

### For Pharmaceutical Trials (FDA Primary, GDPR Secondary)
**Features Needed**:
- ‚úÖ FDA critical features (system validation, protocol compliance, AE management)
- ‚úÖ Audit trail (robust for FDA)
- ‚úÖ Data correction workflow (FDA-grade)
- ‚úÖ Electronic signatures
- ‚ö†Ô∏è GDPR compliance (with FDA legal hold exception)

**Timeline**: 4-5 weeks (FDA Tier 1) + 4-5 weeks (FDA Tier 2) = 8-10 weeks
**Developers**: 2-3

---

### For International Pharmaceutical Trials (FDA + GDPR Both Critical)
**Features Needed**:
- ‚úÖ FDA Tier 1 & 2 features (system validation, protocol, AE, e-sig)
- ‚úÖ GDPR features (data rights, encryption, consent, legal hold)
- ‚úÖ Conflict resolution (legal hold for GDPR deletion requests)

**Timeline**: 5-6 weeks (GDPR) + 8-10 weeks (FDA) = 13-16 weeks
**Developers**: 2-3

**Key Challenge**: GDPR Article 17 (Right to Erasure) vs FDA retention requirements
**Solution**: Already designed in COMPREHENSIVE_FEATURE_ROADMAP.md
- Mark data as "restricted" (Article 18)
- Anonymize identifiers
- Retain de-identified data for regulatory hold
- Both regulations satisfied

---

## PART 6: ZZEDC FDA COMPLIANCE SUMMARY

### Current FDA Compliance Score: 35-40/100 ‚ö†Ô∏è

**Strong Areas**:
- ‚úÖ Audit trail system (comprehensive)
- ‚úÖ User access control (role-based)
- ‚úÖ Basic data integrity (validation framework designed)
- ‚úÖ Password/session controls

**Critical Gaps**:
- ‚ùå System validation (IQ/OQ/PQ) framework ‚Äì CRITICAL
- ‚ùå Protocol compliance monitoring ‚Äì CRITICAL
- ‚ùå Electronic signatures ‚Äì CRITICAL
- ‚ùå AE/SAE management ‚Äì CRITICAL for safety
- ‚ö†Ô∏è Data correction workflow (incomplete)
- ‚ö†Ô∏è Change control (designed, not implemented)
- ‚ö†Ô∏è Backup/recovery procedures (partial)

### To Achieve FDA Compliance: 70-80/100 ‚úÖ

**Total Effort Required**:
- **FDA Tier 1 (Critical)**: 4-5 weeks, 2 developers
- **FDA Tier 2 (High)**: 4-5 weeks, 1-2 developers
- **FDA Tier 3 (Medium)**: 3-4 weeks, 1 developer
- **Total**: 12-14 weeks, 2-3 developers

**Recommendation**: Implement FDA Tier 1 + Tier 2 (8-10 weeks) for pharmaceutical trial readiness

---

## REFERENCES

- FDA Title 21 CFR Part 11: Electronic Records; Electronic Signatures
- FDA Guidance for Industry: Part 11, Electronic Records; Electronic Signatures (2003)
- FDA Guidance for Industry: Data Integrity and Compliance With CGMP (2016)
- FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations (2007)
- FDA Guidance for Industry: Clinical Trial Management Systems (2013)
- ICH GCP E6(R2): Good Clinical Practice Consolidated Guidance (2018)
- ALCOA+ Principles: Attributable, Legible, Contemporaneous, Original, Accurate, Plus Complete, Consistent, Enduring, Available

---

**Prepared By**: Claude Code Analysis
**Date**: December 2025
**Status**: Comprehensive FDA requirement analysis for ZZedc platform
